New longer-acting treatment options for HIV may be on the horizon. A new phase 2 study presented at CROI 2025 has found 96% viral suppression in people with HIV who were taking lenacapavir (Sunlenca, Gilead) plus two broadly neutralizing antibodies (bNAbs). Investigator Onyema Ogbuagu, MBBCh, FACP, FIDSA, spoke to Infectious Disease Special Edition about his results and the potential that bNAbs hold for the future. Dr. Ogbuagu is an associate professor of medicine (AIDS) and of pharmacology and the director of the Yale Antivirals and Vaccines Research program at the Yale School of Medicine, in New Haven.